Literature DB >> 15479842

Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Sadahiro Tamiya1, Sek Mardy, Mark F Kavlick, Kazuhisa Yoshimura, Hiroaki Mistuya.   

Abstract

A variety of amino acid substitutions in the protease and Gag proteins have been reported to contribute to the development of human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors. In the present study, full-length molecular infectious HIV-1 clones were generated by using HIV-1 variants isolated from heavily drug-experienced and therapy-failed AIDS patients. Of six full-length infectious clones generated, four were found to have unique insertions (TGNS, SQVN, AQQA, SRPE, APP, and/or PTAPPA) near the p17/p24 and p1/p6 Gag cleavage sites, in addition to the known resistance-related multiple amino acid substitutions within the protease. The addition of such Gag inserts mostly compromised the replication of wild-type HIV-1, whereas the primary multidrug-resistant HIV infectious clones containing inserts replicated significantly better than those modified to lack the inserts. Western blot analyses revealed that the processing of Gag proteins by wild-type protease was impaired by the presence of the inserts, whereas that by mutant protease was substantially improved. The present study represents the first report clearly demonstrating that the inserts seen in the proximity of the Gag cleavage sites in highly multi-PI resistant HIV-1 variants restore the otherwise compromised enzymatic activity of mutant protease, enabling the multi-PI-resistant HIV-1 variants to remain replication competent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479842      PMCID: PMC523239          DOI: 10.1128/JVI.78.21.12030-12040.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Mechanism of HIV-1 reverse transcriptase. Termination of processive synthesis on a natural DNA template is influenced by the sequence of the template-primer stem.

Authors:  J Abbotts; K Bebenek; T A Kunkel; S H Wilson
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

2.  Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.

Authors:  Oscar Gallego; Carmen de Mendoza; Angélica Corral; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

3.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

4.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Authors:  D D Ho; T Toyoshima; H Mo; D J Kempf; D Norbeck; C M Chen; N E Wideburg; S K Burt; J W Erickson; M K Singh
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

7.  The effects of dNTP pool imbalances on frameshift fidelity during DNA replication.

Authors:  K Bebenek; J D Roberts; T A Kunkel
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

8.  Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.

Authors:  T Shirasaka; R Yarchoan; M C O'Brien; R N Husson; B D Anderson; E Kojima; T Shimada; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

10.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

Authors:  R W Shafer; M J Kozal; M A Winters; A K Iversen; D A Katzenstein; M V Ragni; W A Meyer; P Gupta; S Rasheed; R Coombs
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

View more
  26 in total

1.  Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.

Authors:  Chris M Parry; Madhavi Kolli; Richard E Myers; Patricia A Cane; Celia Schiffer; Deenan Pillay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

Review 2.  Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Authors:  Mark A Winters; Thomas C Merigan
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

Authors:  Kazuhiko Ide; Manabu Aoki; Masayuki Amano; Yasuhiro Koh; Ravikiran S Yedidi; Debananda Das; Sofiya Leschenko; Bruno Chapsal; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

5.  A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.

Authors:  Manabu Aoki; Simon B Chang; Debananda Das; Cuthbert Martyr; Nicole S Delino; Yuki Takamatsu; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Glob Health Med       Date:  2019-10-31

6.  Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.

Authors:  Maria C Puertas; Maria J Buzón; Mònica Ballestero; Peter Van Den Eede; Bonaventura Clotet; Julia G Prado; Javier Martinez-Picado
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

7.  Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

Authors:  Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Kazuhiko Ide; Debananda Das; Yasuhiro Koh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

8.  Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Authors:  Yuki Takamatsu; Manabu Aoki; Haydar Bulut; Debananda Das; Masayuki Amano; Venkata Reddy Sheri; Ladislau C Kovari; Hironori Hayashi; Nicole S Delino; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

9.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.

Authors:  Moisés A Árquez; Samara Martín-Alonso; Robert J Gorelick; Walter A Scott; Antonio J Acosta-Hoyos; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.